Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Biopsy 6trametinib 2olaparib 2dehydroftorafur 2cobimetinib 2atezolizumab 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Capecitabine 2varlilumab 1tremelimumab 1tofacitinib 1tivozanib 1pevonedistat 1peposertib 1pembrolizumab 1nilotinib 1fludarabine 1durvalumab 1ceralasertib 1binimetinib 1avelumab 1aldesleukin 1Taxes 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cholangiocarcinoma × ceralasertib × Clear all
NCT03878095 2026-06-01

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
24 enrolled 12 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡